Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
China Rongtong Academy of Sciences Group is a prominent subsidiary of the state-owned China Rongtong Asset Management Group, established to centralize and manage scientific research assets formerly affiliated with the Chinese military. The group operates as a high-tech innovation hub, focusing heavily on life sciences, biotechnology, and pharmaceutical development. Its core mission involves the translation of advanced military medical research into civilian healthcare applications, including the development of vaccines, emergency medicines, and diagnostic tools. The company oversees several specialized research institutes that contribute to national biosecurity and public health infrastructure. By bridging the gap between defense-related R&D and the commercial market, the Academy plays a critical role in China's national strategy for military-civilian integration. Its portfolio includes significant contributions to global health, such as the development of recombinant vaccines for infectious diseases.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on China Rongtong Academy of Sciences Group.